Gastroesophageal Reflux Disease (GERD) Clinical Trial
— PepsinOfficial title:
Correlation of Oropharyngeal Pepsin and Gastroesophageal (GE) Reflux
Verified date | March 2013 |
Source | Wake Forest University Health Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this research study is to see if GE reflux events are associated with
increasing levels of pepsin in spit samples. Pepsin is a special protein called an "enzyme"
that is made only in your stomach. It is not normally found in your throat. Pepsin breaks
down food proteins that you eat to form nutritional building blocks that your body can use
to grow. An enzyme is a substance that helps break down proteins.
Gastroesophageal reflux disease (GERD) is very common in infants and children, but can
result in serious health problems if not accurately diagnosed. The investigators currently
do not have a definitive test to be used as a standard for diagnosing pediatric GERD.
Measurement of pepsin, an enzyme normally produced only in the stomach, has been used as a
non-invasive way to detect gastric aspiration (reflux of stomach fluid into the airway) in
both adults and children, but using pepsin to detect reflux has not been tested. Since
pepsin should not be present in the normal esophagus and respiratory tract, but is always
present in reflux fluid from the stomach, the investigators believe that the more GE reflux
the investigators detect, the higher the levels of pepsin the investigators see in the fluid
collected from the mouth. If patients do not have GE reflux, but have swallowing problems
alone in which food or liquid goes into the airway, the investigators expect that these
patients will have no pepsin in the fluid collected from their mouth.
The investigators will test these hypotheses by measuring pepsin levels from mouth fluid and
comparing them with the number of GE reflux events the investigators find using the
pH/impedance (MII (multichannel intraluminal impedance)) test. Since the investigators are
interested in pepsin levels for all types of reflux - acid and non-acid -the investigators
will study children whether or not they are on acid blocking medicines. The investigators
will also look at pepsin levels in patients whose pH/MII is normal, but have aspiration
alone that the investigators find on a modified barium swallow (MBS) study. The
investigators will measure pepsin levels in healthy children with no reflux symptoms and no
swallowing problems as the investigators controls. The investigators anticipate that this
study will show a positive correlation between GE reflux events and the presence of
oropharyngeal pepsin, which may allow us to use pepsin as a way to test for reflux.
Status | Completed |
Enrollment | 143 |
Est. completion date | October 2013 |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1. Pediatric patients from birth to 18 years (including premature infants) who are deemed clinically to require 24 hour esophageal pH/impedance. 2. Pediatric patients (newborn to 18 years) undergoing MBS who have had or will have pH/MII monitoring within 6 months. 3. Patients' parents or legal guardians will provide written informed consent for the protocol. When appropriate, patient assent will be obtained. Exclusion Criteria: 1. Patients with anatomic facial anomalies or facial discomfort precluding nasal intubation of the pH/MII catheter. 2. Patient unable to complete a 24 hour pH/MII study. 3. Children fed exclusively with nasogastric or nasojejunal (transpyloric) tube at the time of study. |
Country | Name | City | State |
---|---|---|---|
United States | Wake Forest University Baptist Medical Center | Winston Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Wake Forest University Health Sciences | Takeda |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Positive correlation between GE reflux events and oropharyngeal pepsin concentrations | Total number of GE reflux events by MII over 24 hours. Events will be further subdivided into acid or non-acid based on distal pH measurements. Total number of GE reflux events by MII over 24 hours will be classified as distal, mid, or proximal esophagus. Proximal events will be classified as acid or non-acid based on proximal pH sensor recordings. Esophageal clearance time for all GE reflux events. Oropharyngeal pepsin concentration immediately before and 30 minutes after feeds. Oropharyngeal pepsin concentration after awakening. |
24 Hours | |
Primary | Compare oropharyngeal pepsin concentrations in patients with GE reflux to a. patients with normal pH/MII and isolated oral aspiration on MBS b. healthy controls. | 24 hours | ||
Secondary | Non-acid GE reflux events are positively correlated with increasing levels of oropharyngeal pepsin. | Total number of GE reflux events by MII over 24 hours. Events will be further subdivided into acid or non-acid based on distal pH measurements. Total number of GE reflux events by MII over 24 hours will be classified as distal, mid, or proximal esophagus. Proximal events will be classified as acid or non-acid based on proximal pH sensor recordings. Esophageal clearance time for all GE reflux events. Oropharyngeal pepsin concentration immediately before and 30 minutes after feeds. Oropharyngeal pepsin concentration after awakening. |
24 hours | |
Secondary | Patients with isolated oral aspiration (without GE reflux) will have no oropharyngeal pepsin. | Total number of GE reflux events by MII over 24 hours. Events will be further subdivided into acid or non-acid based on distal pH measurements. Total number of GE reflux events by MII over 24 hours will be classified as distal, mid, or proximal esophagus. Proximal events will be classified as acid or non-acid based on proximal pH sensor recordings. Esophageal clearance time for all GE reflux events. Oropharyngeal pepsin concentration immediately before and 30 minutes after feeds. Oropharyngeal pepsin concentration after awakening. |
24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03561883 -
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
|
Phase 3 | |
Completed |
NCT02555852 -
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
|
N/A | |
Completed |
NCT01406210 -
RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol
|
N/A | |
Terminated |
NCT01327963 -
Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study
|
N/A | |
Completed |
NCT01570842 -
Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury
|
N/A | |
Completed |
NCT02141711 -
TAK-438 - Safety, Blood Levels & Effects of Repeated Doses
|
Phase 1 | |
Terminated |
NCT00587275 -
Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI
|
Phase 2 | |
Completed |
NCT00228527 -
Esomeprazole for Treatment of GERD in Pediatric Patients
|
Phase 4 | |
Completed |
NCT00261300 -
Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)
|
Phase 3 | |
Recruiting |
NCT04506593 -
Indiana University Gastrointestinal Motility Diagnosis Registry
|
||
Completed |
NCT00795093 -
Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US
|
N/A | |
Completed |
NCT00394472 -
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
|
Phase 2 | |
Completed |
NCT00574925 -
Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients
|
Phase 4 | |
Terminated |
NCT02749071 -
An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux
|
N/A | |
Recruiting |
NCT01129713 -
Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.
|
Phase 1/Phase 2 | |
Completed |
NCT00734747 -
Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
|
Phase 3 | |
Completed |
NCT00312806 -
Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)
|
Phase 3 | |
Not yet recruiting |
NCT05579587 -
Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients
|
||
Recruiting |
NCT02366169 -
Medigus Ultrasonic Surgical Endostapler (MUSE) Registry
|
N/A | |
Completed |
NCT01374074 -
Racial Disparity in Barrett's Esophagus
|
N/A |